GetHealthyCalculators
Skip to content

GLP-1 Cost Calculator

GLP-1 obesity therapy is expensive. Branded Wegovy, Zepbound, and Saxenda typically run $1,000–$1,350 per month at the cash pharmacy counter. Compounded options from licensed 503A pharmacies land at roughly $200–$400 per month while FDA shortage status persists. Medicare Part D coverage is evolving — the 2026 IRA-negotiated cap places some formulary-covered products near $50 per month out-of-pocket. This calculator gives a ballpark total by drug, source, and months of therapy.

Reviewed by GetHealthyCalculators Editorial Team · Updated April 14, 2026

Quick Answer

Expect roughly $1,000–$1,350 per month for branded Wegovy, Zepbound, or Saxenda at cash pharmacy prices in 2026. Compounded alternatives run $200–$400 per month where legally available. Medicare-covered GLP-1s can be as low as $50 per month for eligible formularies.

These results are estimates based on general formulas and are not a substitute for professional medical advice. Consult a healthcare provider before making health decisions.

How the Formula Works

  1. Select the GLP-1 drug (semaglutide, tirzepatide, or liraglutide).

    Drug: semaglutide | tirzepatide | liraglutide
  2. Select the pricing source (branded, compounded, Medicare-covered 2026).

    Source: branded | compounded | medicare_2026
  3. Multiply monthly cost by months on therapy.

    Total = Monthly x Months

Methodology & Sources

Reviewed and updated April 14, 2026 · Prepared by GetHealthyCalculators Editorial Team

Values are rounded consumer-facing list prices from Q1 2026 public reporting (GoodRx price trackers, manufacturer disclosures, CMS IRA documentation). This is not financial advice.

References

  • GoodRx — Semaglutide, Tirzepatide, Liraglutide price trackers (Q1 2026) · GoodRx
  • CMS Inflation Reduction Act Part D Negotiation List · Centers for Medicare & Medicaid Services
  • KFF. GLP-1 affordability and Medicare coverage analysis (2024–2026) · KFF (Kaiser Family Foundation)

Limitations

  • Pricing shifts quickly — check the manufacturer and pharmacy for current numbers.
  • Compounded availability depends on FDA shortage status. Legal access may change if branded drugs leave the FDA shortage list.
  • Medicare coverage for obesity-indication GLP-1s remains plan-dependent and may not apply to all beneficiaries.
  • Specialty pharmacy networks, mail order, and manufacturer coupons can change actual out-of-pocket materially.

Frequently Asked Questions

Why is branded so expensive?
Novo Nordisk and Eli Lilly set US list prices well above European prices. Branded cash-pay pricing reflects list price minus limited rebates for uninsured patients. Most insured patients pay less via plan pricing, but insurance coverage for obesity-indication is spotty.
Is compounded GLP-1 legal?
Under FDA 503A rules, licensed compounding pharmacies can make a drug in shortage. Semaglutide and tirzepatide moved on and off the shortage list repeatedly through 2024–2025. When either drug is off-shortage, compounded versions of that drug become legally problematic. Check the FDA drug-shortage page before committing.
What about Medicare?
Medicare Part D historically did not cover anti-obesity medications. The Inflation Reduction Act changed negotiation structure, and specific GLP-1s (starting with semaglutide for cardiovascular indications) are entering negotiated pricing. For pure obesity indication, coverage remains plan-dependent in 2026. Check your Part D formulary.
Can I switch drugs to save money?
Yes, switching between semaglutide, tirzepatide, and liraglutide is common when insurance coverage or pricing changes. There is no fixed equivalent-dose conversion, so any switch should be titrated from the starting dose of the new drug under clinician supervision.

See the typical dosage schedule so you know what you are paying for each week

GLP-1 Dosage Schedule Calculator

More on This Topic